Abstract
Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.
MeSH terms
-
Acinetobacter Infections / drug therapy*
-
Acinetobacter Infections / microbiology
-
Acinetobacter baumannii / drug effects
-
Aged
-
Anti-Bacterial Agents / therapeutic use
-
Colistin / therapeutic use*
-
Drug Resistance, Multiple, Bacterial*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nebulizers and Vaporizers
-
Pneumonia, Bacterial / drug therapy*
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects
-
Retrospective Studies
Substances
-
Anti-Bacterial Agents
-
Colistin